0.48
-0.83%
Close of 9 Nov 2026, in SEK
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Neola Medical
Its shares trade on Nasdaq Stockholm under the ticker NEOLA.ST. It has been listed since 2 October 2020. In the fiscal year to 31 December 2021, it reported revenue of SEK 625,000 and a net loss of SEK 6.7m. At that date it held total assets of SEK 43.8m and shareholders' equity of SEK 40.6m.
Neola Medical AB engages in the research, development, and commercialization of medical devices. The company is headquartered in Lund, Skane. The company went IPO on 2020-10-02. The firm's business concept is to commercialize the Company's medical technology product for continuous lung monitoring based on the patented GASMAS (Gas in Scattering Media Absorption Spectroscopy) technology. Neola Medical's technology equipment aims for continuous monitoring of the lungs of premature babies. The primary purpose of Neola Medical is to support neonatal intensive care with NEOLA, a medical device that can offer continuous lung monitoring and real-time alerts about life-threatening complications using new technology that measures lung volume changes and oxygen concentration.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 2 Oct 2020
- Website
- gpxmedical.se ↗
Leadership
Pay as last reported
- Hanna Sjöström, MBAChief Executive Officer, since 2019
- Märta Lewander Xu, PhDChairman, since 2016
- Urban OttossonChief Financial Officer & Director, since 2020
- Urban OttossonChief Financial Officer & Director, since 2020
- Helene HartmanIndependent Director, since 2021
- Johannes Swartling, PhDIndependent Director, since 2021
- Katarina Svanberg, MD, PhDIndependent Director, since 2016
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Neola Medical AB's IPO on October 2020 provided capital for research and development of medical devices.
- The company's GASMAS technology is a patented method for continuous lung monitoring in premature babies.
- Neola Medical AB is headquartered in Lund, Skane, Sweden, supporting its Health Care sector operations.
Weaknesses
- Neola Medical AB's business concept focuses solely on the NEOLA medical device for neonatal care.
- The company's commercialization efforts are limited to the Health Care industry in Sweden.
- Neola Medical AB has only one product, NEOLA, for continuous lung monitoring in premature babies.
Opportunities
- The global market for neonatal intensive care devices presents growth potential for Neola Medical AB.
- Expanding the GASMAS technology to other medical applications could increase market reach.
- The Health Care sector in Sweden offers opportunities for partnerships with local hospitals.
Threats
- Competition from other medical device companies in the Health Care sector may impact Neola Medical AB's market share.
- Regulatory changes in the Health Care industry could affect the commercialization of NEOLA.
- Dependence on a single product, NEOLA, poses a risk if market demand decreases.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.